Neurology and therapy 2025 Dec 18. doi: 10.1007/s40120-025-00874-z. Online ahead of print. Peter J Goadsby , Alexandra J Sinclair , Shazia K Afridi , Christian Lucas , Jerôme Mawet , Michel Lanteri-Minet , Xavier Moisset , Hans Christoph Diener , Charly Gaul , Tim Patrick Jürgens , Marja-Liisa Sumelahti , Margarita Sanchez
Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study
The Journal of Headache and Pain 2025 Jul 2;26(1):153. doi: 10.1186/s10194-025-02086-0. M Lanteri-Minet , C Casarotto, O Bretin, C Collin, M Gugenheim, V Raclot, A Cases, P A Squara, W Aissani, A Saighi, H Lefebvre Abstract Background: The most used treatments for migraine attacks are triptans, yet a considerable proportion of
The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023 Sep;20(5):1305-1315.doi: 10.1007/s13311-023-01404-1. Epub 2023 Jul 12. Diane Merino, Alexandre O Gérard, Elise K Van Obberghen, Alexandre Destere, Michel Lanteri-Minet, Milou-Daniel Drici Abstract Migraine constitutes the world’s second-leading cause of disability. Triptans, as